This report also provides a detailed analysis of the current mucopolysaccharidosis marketed drugs and late-stage pipeline ...

Ultragenyx's high burn rate, costly R&D, and recent setbacks increase dilution risk, impacting future profitability. Learn ...

However, the market is constrained by challenges such as complex implementation and high costs. Nevertheless, there are ...

Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.